From the Day Trading thread:
Neuron Pharmaceuticals is developing a drug to treat Traumatic Brain Injuries (TBI) with its lead candidate NNZ-2566 due to enter phase II trials in late 2012. TBI is targeted at a very large unmet need and it is a space with few competitors with a potential market in the billions of dollars per annum. The US Army and NHMRC are funding the upcoming trials with US$23m in grants. Because of the unmet need NNZ-2566 has been granted Fast Track Status with the US FDA which helps facilitate communication. The level of interest in the company is clearly on the rise with a Bell Potter report released this week giving a price target of 12 cents and an optimistic case of 21 cents. News Due: Exception from informed consent approval by FDA. Results of in vivo assessment of cancer antibodies (Perseis). Price Target: A close above 2.4 cents gives a target of 3.0 / 3.1 cents. Disclosure: Holding NEU
From the Day Trading thread:Neuron Pharmaceuticals is developing...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.88 |
Change
-0.830(4.97%) |
Mkt cap ! $2.043B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.82 | $2.354M | 146.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 537 | $15.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.90 | 472 | 7 |
View Market Depth
| Last trade - 11.34am 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |